Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others

Report Details
Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others – our new study reveals trends, R&D progress, and predicted revenues
Where is the Osteoporosis Drugs market heading? Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 207 page report provides 140 charts. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Osteoporosis Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
- In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
- You find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
- Read full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
- Interview with Paul Mitchell, founder of Synthesis Medical, an independent healthcare consultancy
- Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist at Pursuit Physical Therapy

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: Antiresorptive drugs, Anabolic drugs and Others. These submarkets are further broken down into bisphosphonates, selective oestrogen receptor modulators, RANKL antibodies and the parathyroid hormones.
Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those Osteoporosis Drugs?
How will individual osteoporosis drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these 13 brands:
1. Fosamax
2. Boniva/Bonviva
3. Actonel/Atelvia
4. Reclast/Aclasta
5. Recalbon/Bonoteo
6. Evista
7. Duavee
8. Prolia
9. Forteo
10. Odanacatib
11. Romosozumab
12. Protelos
13. Abaloparatide

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:
- United States (US)
- Japan
- Germany, France, the UK, Italy and Spain (EU5 group)
- Brazil, Russia, India and China (BRIC countries).
- South Korea

Leading companies and the potential for market growth
You can also see which companies hold the most potential:
- Eli Lilly
- Amgen
- UCB
- GSK
- MSD
- Allergan
- Sanofi
- Pfizer
- Novartis
- Radius Health

Research and development - assess innovation, trends and possibilities
Our report discusses R&D, appraising technological, clinical and commercial possibilities.
Our report forecasts prominent pipeline drugs and discusses their submarkets. 3 drugs are forecasted in this chapter with other promising drugs discussed. New submarkets are also introduced; the anti-sclerostin monoclonal antibodies and the cathepsin K inhibitors.

How the Osteoporosis Drugs Market report helps you
Our new report discusses issues and events affecting the osteoporosis market. You will find quantitative and qualitative analyses on:

- Revenue to 2026 for the global osteoporosis drugs market – discover the sales potential of that industry
- Revenues to 2026 for the osteoporosis submarkets – find sales predictions for top treatments, seeing how they can compete and succeed
- Revenue forecasts to 2026 for 13 individual osteoporosis drugs – find the current best selling osteoporosis drug and how this will change over the next 10 years
- Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia – discover the best countries and regions for commercial expansion
- Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances and outlooks, also with industry opinions
- Discussions of R&D – investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities
- Analysis of what stimulates and restrains the osteoporosis market – assess challenges and strengths for those medicines, their developers, producers and sellers, helping you compete and stay ahead.
- Patent expiries and how they will affect the market.
- The challenges facing the market, including the entry of generics on the market.
- How unmet medical needs will fuel growth in emerging markets over the next 10 years
- How next generation therapies will come to dominate the market by the end of the forecast.

Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.

Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2026 for the Osteoporosis drugs market.